P D F - S E A R C H

Нашёл 1 тыс. ответов for 'Ecallantide'.

Overview of ecallantide in the treatment of
Introduction to ecallantide Ecallantide is a potent and specific plasma kallikrein inhibitor that blocks generation of bradykinin. Pharmacodynamics Ecallantide delays thrombin generation in vitro [25].

https://www.openaccessjournals.com/articles/overview-of-ecallantide-in-the-treatment-of-hereditary-angioedema-types-i-and-ii.pdf

Ecallantide
Ecallantide. This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take If you have an allergy to ecallantide or any other part of this.

https://www.mskcc.org/pdf/cancer-care/patient-education/ecallantide-01?mode=large

label
KALBITOR (ecallantide) is a human plasma kallkrein inhibitor for injection for subcutaneous use. Each vial. contains 10 mg ecallantide as the active ingredient, and the following inactive ingredients

https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125277lbl.pdf

Kalbitor (ecallantide)
The REMS for Kalbitor (ecallantide) was originally approved on December 1, 2009, and the most recent REMS modification was approved on April 5, 2011. The REMS consists of a Medication Guide...

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125277s037ltr.pdf

KALBITOR® (ecallantide)
Active Ingredient: ecallantide. Inactive ingredients: disodium hydrogen orthophosphate (dihydrate), monopotassium phosphate, potassium chloride, sodium chloride in water for injection.

https://www.fda.gov/media/77784/download

Clinical Policy: Ecallantide (Kalbitor
Description Ecallantide (Kalbitor®) is a plasma kallikrein inhibitor. FDA Approved Indication(s) Kalbitor is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients. 12 years of age...

https://ambetter.superiorhealthplan.com/content/dam/centene/policies/pharmacy-policies/CP.PHAR.177%20Ecallantide.pdf

Clinical Policy: Ecallantide (Kalbitor
Description Ecallantide (Kalbitor®) is a plasma kallikrein inhibitor. FDA Approved Indication(s) Kalbitor is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients. 12 years of age...

https://www.superiorhealthplan.com/content/dam/centene/policies/pharmacy-policies/CP.PHAR.177%20Ecallantide.pdf

Microsoft Word - CP.PHAR.177 Ecallantide (Kalbitor) 12.03.19_clean
Description Ecallantide (Kalbitor®) is a plasma kallikrein inhibitor. FDA Approved Indication(s) Kalbitor is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients.

https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/pharmacy-policies/Ecallantide%20(Kalbitor)%20(CP.PHAR.177)%20(PDF).pdf

MG_Kalbitor_ecallantide.pdf
Kalbitor® (ecallantide). Last Review Date: October 14, 2019. Kalbitor (ecallantide) is considered medically necessary for the treatment of acute attacks of hereditary angioedema when the following...

https://www.emblemhealth.com/content/dam/emblemhealth/pdfs/provider/medical_policies/k/MG_Kalbitor_ecallantide.pdf

Policy: MBP 86.0 | I. Policy: Kalbitor (ecallantide)
Kalbitor (ecallantide) will be considered medically necessary for the treatment of acute attacks of hereditary angioedema in patients 12 years of age and older when the following criteria are met

https://www.geisinger.org/-/media/OneGeisinger/Files/Policy-PDFs/MBP/51-100/MBP-086-Kalbitor-ecallantide.pdf?la=en